ID: ALA94655

Max Phase: Preclinical

Molecular Formula: C20H20F2N2O2

Molecular Weight: 358.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(CC2NCCc3c2[nH]c2c(F)cc(F)cc32)cc1OC

Standard InChI:  InChI=1S/C20H20F2N2O2/c1-25-17-4-3-11(8-18(17)26-2)7-16-20-13(5-6-23-16)14-9-12(21)10-15(22)19(14)24-20/h3-4,8-10,16,23-24H,5-7H2,1-2H3

Standard InChI Key:  HGPUOFMXABMTJJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 358.39

Molecular Weight (Monoisotopic): 358.1493

AlogP: 3.89

#Rotatable Bonds: 4

Polar Surface Area: 46.28

Molecular Species: BASE

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.22

CX LogP: 3.63

CX LogD: 1.82

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.74

Np Likeness Score: 0.18

References

1. Audia JE, Evrard DA, Murdoch GR, Droste JJ, Nissen JS, Schenck KW, Fludzinski P, Lucaites VL, Nelson DL, Cohen ML..  (1996)  Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.,  39  (14): [PMID:8709108] [10.1021/jm960062t]

2. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R..  (2021)  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.,  64  (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887]

Source

Source(1):

• Scientific Literature